AADs |
Antiangiogenesis drugs |
AATs |
Antiangiogenic therapy |
ABC |
ATP-binding cassette transporter family |
ACRT |
Association for Clinical Research Training |
Ang 2 |
Angiopoietin 2 |
bFGF |
basic fibroblast growth factor |
CAII |
Carbonic anhydrase 2 |
CECs |
Circulating endothelial cells |
COX2 |
Cyclooxygenase 2 |
CSC |
Cancer stem cells |
CT |
Computed tomography |
DCE-US |
Dynamic contrast-enhanced ultrasonography |
EC |
Endothelial cells |
ECT |
Emission computed tomography |
EGFR |
Epidermal growth factor receptor |
EPC |
Endothelial progenitor cells |
EPR |
Enhanced permeability and retention |
FASN |
Fatty acid synthase |
HEVs |
High endothelial venules |
IFN |
Interferon |
IGF-1 |
Insulin-like growth factor |
IL |
Interleukin |
mTOR |
Mammalian target of rapamycin |
miR |
MicroRNA |
MDR1 |
Multidrug resistance protein 1 |
MMPs |
Matrix metalloproteinases |
MRI |
Magnetic resonance imaging |
NEC |
Normal endothelial cells |
PDGF |
Platelet-derived growth factor |
PECAM1 |
Platelet endothelial cell adhesion molecule 1 |
PFKFB3 |
Phosphofructokinase-2/fructose-2,6-bisphosphatase 3 |
PGE2 |
Prostaglandin E2 |
PHGDH |
D-3-phosphoglycerate dehydrogenase |
PSAT1 |
Phosphoserine aminotransferase 1 |
Sca-1 |
Stem cell antigen-1 |
SDF-1 |
Stromal cell-derived factor-1 |
TAMs |
Tumor-associated macrophages |
TEC |
Tumor endothelial cells |
TEMs |
Tumor endothelial markers |
TKIs |
Tyrosine kinase inhibitors |
TP53 |
Tumor protein p53 |
VEGF |
Vascular endothelial growth factor |
VEGFR |
Vascular endothelial growth factor receptor |